Caifeng Fu

5.0k citations

14 papers · 4.3k indexed · 3 hit papers · h-index 9

Impact in

Clinical Biochemistry top 0.02%
- Advanced Glycation End Products research
Endocrinology, Diabetes and Metabolism top 1%
- Natural Antidiabetic Agents Studies
- Diabetes, Cardiovascular Risks, and Lipoproteins

Papers in

Clinical Biochemistry 6
- Advanced Glycation End Products research 5
Virology 3
- HIV Research and Treatment 3

Co-authors: Ann Marie Schmidt David M. Stern Thomas Kislinger Wu Qu M. Hofmann Akihiko Taguchi Monika Pischetsrieder Nozomu Tanji
Journals: Open Forum Infectious Diseases (1 paper)Gastroenterology (1 paper)Journal of the American Society of Nephrology (1 paper)Digestive Diseases and Sciences (1 paper)Journal of Biological Chemistry (1 paper)
Partner nations: United States United Kingdom Germany

In The Last Decade

Caifeng Fu

14 papers receiving 4.3k citations

Hit Papers

align trajectories log scale

Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases 2000 · 1.1k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2000 Nature
1999 Journal of Biological Chemistry
1999 Cell

Peers

Countries citing papers authored by Caifeng Fu

Since Specialization

Citations

This map shows the geographic impact of Caifeng Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caifeng Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caifeng Fu more than expected).

Fields of papers citing papers by Caifeng Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caifeng Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caifeng Fu. The network helps show where Caifeng Fu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Caifeng Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Caifeng Fu Line = papers co-authored together Caifeng Fu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Newborn screening for primary carnitine deficiency in Quanzhou, China Clinica Chimica Acta ·Weihua Lin, 蒋峥峥, Zhenzhu Zheng, Yanru Chen, Caifeng Fu, Yiming Lin, Dongmei Chen	2020	10
2	<p>The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet</p> Clinical Pharmacology Advances and Applications ·Rashmi Mehta, Joseph Piscitelli, 峯廻直美, Caifeng Fu, Herta Crauwels, Brian Wynne, Kimberly K. Adkison	2020	3
3	Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine Clinical Pharmacology in Drug Development ·Teodora Pene Dumitrescu, A Khoshbin, Caifeng Fu, Kalpana Bakshi, Shui Yu, Zhiping Zhang, Allan R. Tenorio, Dean Sylvaria, Robert Strouse, 峯廻直美, Kimberly K. Adkison	2019	6
4	A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants Clinical Pharmacology in Drug Development ·孫寧一, Susan L. Ford, Yu Lou, Caifeng Fu, Kalpana Bakshi, Allan R. Tenorio, 刘丰英, William Spreen, Parul Patel	2019	16
5	Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection Antimicrobial Agents and Chemotherapy ·Rashmi Mehta, 峯廻直美, Alessandra Maria Lima Lisboa Costa, Caifeng Fu, Robert Strouse, Herta Crauwels, Naomi Givens, Simon Vanveggel, Brian Wynne, Kimberly K. Adkison	2018	8
6	Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment Open Forum Infectious Diseases ·孫寧一, Susan L. Ford, Yu Lou, Caifeng Fu, Kalpana Bakshi, Allan R. Tenorio, 刘丰英, William Spreen, Parul Patel	2017	4
7	Pharmacodynamics and Safety of Pantoprazole in Neonates, Preterm Infants, and Infants Aged 1 Through 11 Months with a Clinical Diagnosis of Gastroesophageal Reflux Disease Digestive Diseases and Sciences ·Jarosław Kierkuś, Wanda Furmaga-Jabłońska, Janice E. Sullivan, Elmer S David, Dan L. Stewart, Natalie Rath, Caifeng Fu, Alphonse Jeanneret-Grosjean, Mary K. Maguire, Gail M. Comer	2010	21
8	M1908 Pharmacodynamics (PD) and Safety of Pantoprazole Delayed-Release Granules in Infants Aged 1 Through 11 Months with a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD) Gastroenterology ·Gail M. Comer, Jarosław Kierkuś, Janice E. Sullivan, Wanda Furmaga-Jabłońska, Natalie Rath, Caifeng Fu, Wenjin Wang, Mary K. Maguire	2009	2
9	Pharmacokinetics of Two Dose Levels of Pantoprazole Sodium Delayed-Release Granules for Oral Suspension in Infants Aged 1 Through 11 Months with a Presumed Diagnosis of GERD The American Journal of Gastroenterology ·Marika Davies, (unknown), Noel Octaviano, Jarosław Kierkuś, Natalie Rath, Caifeng Fu, Meng Xu, Mary K. Maguire, Gail M. Comer	2008	3
10	Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE Circulation ·Giuseppina Basta, Guido Lazzerini, Marika Massaro, Tommaso Simoncini, Piero Tanganelli, Caifeng Fu, Thomas Kislinger, David M. Stern, Ann Marie Schmidt, Raffaele De Caterina	2002	456
11	Expression of Advanced Glycation End Products and Their Cellular Receptor RAGE in Diabetic Nephropathy and Nondiabetic Renal Disease Journal of the American Society of Nephrology ·Nozomu Tanji, Glen S. Markowitz, Caifeng Fu, Thomas Kislinger, Akihiko Taguchi, Monika Pischetsrieder, David M. Stern, Ann Marie Schmidt, Vivette D. D’Agati	2000	399
12	Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases Nature ·Akihiko Taguchi, Luis Mariano Cubillas Recio, G. Del Toro, Lukáš Holý, 菅原通子, Wu Qu, Nozomu Tanji, Yan Lu, Evanthia Lalla, Caifeng Fu, M. Hofmann, Thomas Kislinger, Mark Ingram, Amy Lu, Hidekazu Tanaka, Osamu Hori, Satoshi Ogawa, David M. Stern, Ann Marie Schmidt Hit paper breakdown →	2000	1058
13	RAGE Mediates a Novel Proinflammatory Axis Cell ·M. Hofmann, C. V. Quinteros Peñafiel, Caifeng Fu, Wu Qu, Akihiko Taguchi, Yan Lü, Cecilia Avila, Neeraja Kambham, Angelika Bierhaus, Peter P. Nawroth, Markus F. Neurath, Timothy Slattery, Dale L. Beach, John McClary, Mariko Nagashima, John Morser, David Stern, Ann Marie Schmidt Hit paper breakdown →	1999	1582
14	N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression Journal of Biological Chemistry ·Thomas Kislinger, Caifeng Fu, Birgit Huber, Wu Qu, Akihiko Taguchi, Shi Du Yan, M. Hofmann, Shi Fang Yan, Monika Pischetsrieder, David M. Stern, Ann Marie Schmidt Hit paper breakdown →	1999	763

About Caifeng Fu

Caifeng Fu is a scholar working on Clinical Biochemistry, Virology, Gastroenterology, Infectious Diseases and Pediatrics, Perinatology and Child Health, having authored 14 papers that have together received 4.3k indexed citations. Recurring topics across this work include Advanced Glycation End Products research (5 papers), HIV/AIDS drug development and treatment (5 papers), Gastroesophageal reflux and treatments (3 papers), HIV Research and Treatment (3 papers), Biochemical and Molecular Research (2 papers), S100 Proteins and Annexins (2 papers), Helicobacter pylori-related gastroenterology studies (2 papers) and Pharmaceutical studies and practices (2 papers). The work is most often cited by research in Clinical Biochemistry (3.1k citations), Endocrinology, Diabetes and Metabolism (1.0k citations), Nephrology (390 citations), Immunology (907 citations) and Neurology (295 citations). Caifeng Fu has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Ann Marie Schmidt, David M. Stern, Thomas Kislinger, Wu Qu, M. Hofmann, Akihiko Taguchi, Monika Pischetsrieder, Nozomu Tanji, Akihiko Taguchi and Cecilia Avila. Their work appears in journals such as Open Forum Infectious Diseases, Gastroenterology, Journal of the American Society of Nephrology, Digestive Diseases and Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact